Wealth Enhancement Advisory Services Portfolio holdings
AUM
$60.4B
1-Year Return
15.61%
This Quarter Return
+8.75%
1 Year Return
+15.61%
3 Year Return
+48.2%
5 Year Return
+69.03%
10 Year Return
+118.46%
AUM
$60.4B
AUM Growth
+$8.15B
(+16%)
Cap. Flow
+$3.79B
Cap. Flow
% of AUM
6.27%
Top 10 Holdings %
Top 10 Hldgs %
23.67%
Holding
3,471
New
502
Increased
1,628
Reduced
1,086
Closed
148
Top Buys
| 1 |
JMTG
JPMorgan Mortgage-Backed Securities ETF
JMTG
|
$141M |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
$129M |
| 3 |
iShares Core S&P Small-Cap ETF
IJR
|
$128M |
| 4 |
ALPS Smith Core Plus Bond ETF
SMTH
|
$126M |
| 5 |
Microsoft
MSFT
|
$113M |
Top Sells
| 1 |
Palantir
PLTR
|
$150M |
| 2 |
JPMorgan Short Duration Core Plus ETF
JSCP
|
$78.1M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
$59.3M |
| 4 |
CBRE Group
CBRE
|
$36.7M |
| 5 |
UnitedHealth
UNH
|
$28.9M |
Sector Composition
| 1 | Technology | 12.76% |
| 2 | Financials | 6.58% |
| 3 | Industrials | 4.51% |
| 4 | Consumer Discretionary | 3.84% |
| 5 | Healthcare | 3.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HPP
3201
Hudson Pacific Properties
HPP
$1.12B
| $48.5K | ﹤0.01% |
+17,816
| New | +$48.5K |
|
3202
Pacific Biosciences
PACB
$375M
| $48.2K | ﹤0.01% |
30,113
+9,739
| +48% | +$15.6K |
|
3203
Sangamo Therapeutics
SGMO
$165M
| $47.7K | ﹤0.01% |
90,550
+21,300
| +31% | +$11.2K |
|
3204
Kosmos Energy
KOS
$789M
| $47.1K | ﹤0.01% |
+23,807
| New | +$47.1K |
|
3205
JetBlue
JBLU
$1.85B
| $47K | ﹤0.01% |
+10,545
| New | +$47K |
|
3206
GoPro
GPRO
$237M
| $46.6K | ﹤0.01% |
62,581
-13,579
| -18% | -$10.1K |
|
3207
NGL Energy Partners
NGL
$734M
| $46.5K | ﹤0.01% |
10,883
| – | – |
|
|
SVC
3208
Service Properties Trust
SVC
$477M
| $46.3K | ﹤0.01% |
17,790
-7,238
| -29% | -$18.8K |
|
3209
Hyperfine
HYPR
$90.4M
| $45.3K | ﹤0.01% |
56,625
+300
| +0.5% | +$240 |
|
3210
Century Therapeutics
IPSC
$43.8M
| $45.1K | ﹤0.01% |
81,247
-3,836
| -5% | -$2.13K |
|
3211
CPI Aerostructures
CVU
$31.7M
| $44.7K | ﹤0.01% |
13,350
+1,850
| +16% | +$6.2K |
|
3212
Chegg
CHGG
$177M
| $44.4K | ﹤0.01% |
30,861
+15,549
| +102% | +$22.4K |
|
3213
Hyliion Holdings
HYLN
$289M
| $44.1K | ﹤0.01% |
+30,616
| New | +$44.1K |
|
3214
Larimar Therapeutics
LRMR
$343M
| $43.6K | ﹤0.01% |
+13,629
| New | +$43.6K |
|
3215
ImmunityBio
IBRX
$2.31B
| $43.3K | ﹤0.01% |
+15,933
| New | +$43.3K |
|
3216
Iovance Biotherapeutics
IOVA
$872M
| $43.3K | ﹤0.01% |
24,735
-2,716
| -10% | -$4.75K |
|
|
OGI
3217
Organigram Holdings
OGI
$217M
| $42K | ﹤0.01% |
29,387
-695
| -2% | -$994 |
|
|
CGC
3218
Canopy Growth
CGC
$440M
| $41.4K | ﹤0.01% |
32,336
+14,498
| +81% | +$18.6K |
|
3219
Oramed Pharmaceuticals
ORMP
$91M
| $41K | ﹤0.01% |
18,799
+5,000
| +36% | +$10.9K |
|
3220
Fate Therapeutics
FATE
$112M
| $39.6K | ﹤0.01% |
35,347
+5,438
| +18% | +$6.09K |
|
3221
iHeartMedia
IHRT
$329M
| $39.4K | ﹤0.01% |
20,187
-7,419
| -27% | -$14.5K |
|
3222
Microvision
MVIS
$331M
| $38.1K | ﹤0.01% |
+33,398
| New | +$38.1K |
|
3223
Nkarta
NKTX
$155M
| $37.8K | ﹤0.01% |
21,620
+4,255
| +25% | +$7.45K |
|
3224
Leslie's
LESL
$64.2M
| $36.8K | ﹤0.01% |
88,094
+50,815
| +136% | +$21.2K |
|
3225
Mersana Therapeutics
MRSN
$34.8M
| $36.7K | ﹤0.01% |
5,069
-159
| -3% | -$1.15K |
|